Therapeutic dilemmas: cognitive enhancers and risk of falling in older adults-a clinical review
- PMID: 37418063
- PMCID: PMC10447592
- DOI: 10.1007/s41999-023-00821-x
Therapeutic dilemmas: cognitive enhancers and risk of falling in older adults-a clinical review
Abstract
Purpose: Cognitive enhancers are the primary pharmacological therapy prescribed to those with dementia, comprising of memantine and the acetylcholinesterase inhibitors (AChEIs). The long-term cognitive and behavioural benefits of these medications, as well as their potential contribution to falls is currently debated, with recent Delphi studies being unable to reach consensus on whether these medications should be deprescribed. In this narrative clinical review, as part of a series on deprescribing in people at risk of falls, we explore the potential falls-related side effects experienced in people taking cognitive enhancers, alongside situations where deprescribing may be appropriate.
Methods: We undertook a literature search of PubMed and Google Scholar, using terms capturing falls and cognitive enhancers, as well as consulting the British National Formulary and published Summary of Medicinal Product Characteristics. These searches informed the subsequent clinical review.
Results: Cognitive enhancers should be subject to regular review, including confirmation of appropriate treatment indication, and occurrence of side effects in the context of falls. AChEIs, in particular, are associated with a broad range of side effects that can contribute to increased falls risk. These include bradycardia, syncope and neuromuscular effects. Where these have been identified, deprescribing should be considered, as well as alternative treatment options. Deprescribing studies have shown mixed results, likely due to considerable methodological heterogeneity. Several suggested guidelines exist to aid deprescribing decisions, many of which are highlighted in this review.
Conclusions: The use of cognitive enhancers should be regularly reviewed and decisions to deprescribe made on a case-by-case basis, considering both the risks and benefits of stopping these medications.
Keywords: Cognitive enhancers; Dementia; Deprescribing; Falls.
© 2023. The Author(s).
Conflict of interest statement
GEP, MDS, and EPP have no relevant financial or non-financial interests to disclose. TW is Research and Medical Director of The Research Institute for the Care of Older People (RICE), which runs a mixture of commercial and non-commercial research activity. Commercial research projects run in the Institute have been funded by: Roche, Biogen, Janssen, AC Immune, Novo Nordisk, and Julius Clinical.
Similar articles
-
Risk for Health Events After Deprescribing Acetylcholinesterase Inhibitors in Nursing Home Residents With Severe Dementia.J Am Geriatr Soc. 2020 Apr;68(4):699-707. doi: 10.1111/jgs.16241. Epub 2019 Nov 26. J Am Geriatr Soc. 2020. PMID: 31769507 Free PMC article.
-
CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia.Alzheimers Dement (N Y). 2022 Jan 31;8(1):e12099. doi: 10.1002/trc2.12099. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35128025 Free PMC article.
-
Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.Health Technol Assess. 2022 Jul;26(32):1-148. doi: 10.3310/AAFO2475. Health Technol Assess. 2022. PMID: 35894932 Free PMC article. Review.
-
ACP Journal Club. Review: cholinesterase inhibitors but not memantine increase syncope in older adults with mild cognitive impairment or dementia.Ann Intern Med. 2011 Nov 15;155(10):JC5-10. doi: 10.7326/0003-4819-155-10-201111150-02010. Ann Intern Med. 2011. PMID: 22084357 No abstract available.
-
Impact of deprescribing dual-purpose medications on patient-related outcomes for older adults near end-of-life: a systematic review and meta-analysis.Ther Adv Drug Saf. 2021 Oct 22;12:20420986211052343. doi: 10.1177/20420986211052343. eCollection 2021. Ther Adv Drug Saf. 2021. PMID: 34707802 Free PMC article. Review.
Cited by
-
Relationship Between Depression and Falls Among Nursing Home Residents: Integrative Review.Interact J Med Res. 2024 Nov 28;13:e57050. doi: 10.2196/57050. Interact J Med Res. 2024. PMID: 39608784 Free PMC article. Review.
-
Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives.ACS Omega. 2025 Jan 8;10(2):1864-1892. doi: 10.1021/acsomega.4c09114. eCollection 2025 Jan 21. ACS Omega. 2025. PMID: 39866628 Free PMC article. Review.
-
Dual Monitoring of Blood Acetylcholinesterase Content and Catalytic Activity Utilizing Fluorometry-Integrated Surface Plasmon Resonance.Biosensors (Basel). 2025 Feb 17;15(2):118. doi: 10.3390/bios15020118. Biosensors (Basel). 2025. PMID: 39997020 Free PMC article.
-
Cognitive dysfunction-an under looked avenue to promote health in incarcerated elderly population through yoga.Front Hum Neurosci. 2025 May 9;19:1553845. doi: 10.3389/fnhum.2025.1553845. eCollection 2025. Front Hum Neurosci. 2025. PMID: 40416901 Free PMC article.
-
Dementia care and mortality in people experiencing homelessness: A matched cohort study.Alzheimers Dement. 2025 Aug;21(8):e70571. doi: 10.1002/alz.70571. Alzheimers Dement. 2025. PMID: 40799142 Free PMC article.
References
-
- World Health Organisation (WHO). Falls—fact sheet 2021. https://www.who.int/news-room/fact-sheets/detail/falls. Accessed 11 Dec 2022
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical